259810-12-3

Basic information

• Product Name: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE
• Synonyms: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-AMINE;6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE;6,7-dihydro-4H-pyrano[4,3-d][1,3]thiazol-2-amine;6,7-Dihydro-4H-pyrano[4,3-d]-1,3-thiazol-2-ylamine;4H,6H,7H-pyrano[4,3-d][1,3]thiazol-2-aMine
• CAS NO: 259810-12-3
• Molecular Formula: C₆H₈N₂OS
• Molecular Weight: 156.20552
• Product Categories: pharmacetical
• Mol File: 259810-12-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 353.65 °C at 760 mmHg
• Flash Point: 167.682 °C
• Appearance: /
• Density: 1.391 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.646
• PKA: 4.73±0.20(Predicted)
• CAS DataBase Reference: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE(259810-12-3)
• EPA Substance Registry System: 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE(259810-12-3)

Safety Data

• Hazardous Substances Data: 259810-12-3(Hazardous Substances Data)

Usage

General Description

6,7-Dihydro-4H-pyrano[4,3-d]thiazol-2-ylamine is a chemical compound with the molecular formula C8H9N3OS. It is a heterocyclic amine containing a thiazole ring fused with a pyran ring. 6,7-DIHYDRO-4H-PYRANO[4,3-D]THIAZOL-2-YLAMINE is known for its potential biological activities and has been studied for its antimicrobial, antifungal, and antitumor properties. It has also been investigated for its potential as a pharmaceutical intermediate in the synthesis of various organic compounds. 6,7-Dihydro-4H-pyrano[4,3-d]thiazol-2-ylamine is an important building block in organic chemistry and has shown promise in various pharmacological applications.

InChI:InChI=1/C6H8N2OS/c7-6-8-4-1-2-9-3-5(4)10-6/h1-3H2,(H2,7,8)

Upstream product

• 17356-08-0 thiourea 
• 420-04-2 CYANAMID 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 123-75-1 pyrrolidine 
• 98021-79-5 3-bromo-tetrahydro-pyran-4-one 
• 160427-98-5 3-chlorodihydro-2H-pyran-4(3H)-one 
• 62936-76-9 1-(3,6-dihydro-2H-pyran-4-yl)pyrrolidine 

Downstream Products

• 1083177-70-1 (Z)-5-chloro-N-(6,7-dihydro-1H-pyrano[4,3-d]thiazol-2(4H)-ylidene)-2-methoxybenzamide 

Relevant articles and documents

Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected β-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF

The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.